Intuitive Surgical INC 8-K filings

Intuitive Surgical, Inc. has updated its bylaws to align with new SEC universal proxy rules and enhance shareholder meeting procedures.

Intuitive Surgical announced robust second quarter 2026 financial results, driven by significant growth in worldwide procedures and system placements, leading to a 19% increase in revenue.

Intuitive Surgical has appointed Taylor Patton as Chief Commercial and Marketing Officer, effective July 1, 2026, succeeding Henry Charlton.

Intuitive Surgical announced robust first-quarter 2026 financial results, driven by significant growth in procedures and system placements.

Intuitive Surgical completed its acquisition of the da Vinci and Ion distribution business from ab medica and affiliates, expanding direct operations across Southern Europe.

Intuitive announced robust fourth-quarter 2025 financial results, driven by significant growth in da Vinci procedures and system placements, alongside a positive outlook for 2026 despite anticipated procedure growth deceleration.

Intuitive Surgical announced robust preliminary fourth quarter and full year 2025 financial results, driven by significant growth in da Vinci and Ion procedures and system placements.

Intuitive Surgical announces a strategic leadership transition for its Chief Digital Officer, Brian E. Miller, effective January 1, 2026.

Intuitive Surgical reported robust third-quarter 2025 financial results, driven by significant procedure growth and increased adoption of its da Vinci and Ion surgical systems.

Intuitive Surgical reported robust second-quarter 2025 financial results, driven by significant growth in da Vinci procedures and strong adoption of its new da Vinci 5 surgical system.

Intuitive Surgical announced that President Dave Rosa will become CEO on July 1, 2025, succeeding Gary Guthart, who will transition to Executive Chair of the Board.

Intuitive Surgical's stockholders approved an amendment to the 2010 Incentive Award Plan and the board authorized a $4 billion increase to the company's stock repurchase program.

Intuitive Surgical reports a 19% increase in revenue for Q1 2025, fueled by growth in da Vinci procedures and system placements.

Intuitive Surgical's Q4 2024 revenue increased by 25% year-over-year, driven by procedure growth and system placements, while the company also announced plans to acquire its distribution businesses in select European countries.

Intuitive Surgical reports preliminary Q4 and full year 2024 results, highlighting significant revenue growth and increased da Vinci surgical system placements and procedures.

Intuitive Surgical has promoted two senior vice presidents to executive vice president roles, accompanied by increases in their base salaries and target bonus opportunities, effective January 1, 2025.

Intuitive Surgical's Q3 2024 results show significant growth in procedures, system placements, and revenue, driven by the adoption of da Vinci technology.

Intuitive Surgical has appointed its President, David J. Rosa, to its Board of Directors and increased the board size to 12 members.

Intuitive Surgical's Q2 2024 results show a 14% revenue increase year-over-year, driven by growth in da Vinci procedures and system placements.

Intuitive Surgical appointed new chairs to the Audit and Governance and Nominating Committees following their 2024 Annual Meeting of Stockholders.

Intuitive Surgical's first quarter results show significant growth in procedure volume, revenue, and net income, driven by increased adoption of their robotic surgical systems.

Intuitive Surgical has announced FDA clearance for its fifth-generation robotic surgical system, da Vinci 5, which includes over 150 enhancements and new force-sensing technology.

Intuitive Surgical's Q4 2023 results show significant growth in procedure volume, system placements, and revenue, with a notable increase in net income.